Celldex Therapeutics (CLDX) Shares Gap Up to $2.75
Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) gapped up prior to trading on Friday . The stock had previously closed at $2.92, but opened at $2.75. Celldex Therapeutics shares last traded at $2.82, with a volume of 1528776 shares trading hands.
A number of analysts have recently commented on the company. Leerink Swann reaffirmed a “market perform” rating and issued a $3.00 price target (down from $4.00) on shares of Celldex Therapeutics in a research note on Thursday. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Celldex Therapeutics in a research note on Thursday. Cantor Fitzgerald reissued a “buy” rating and set a $9.00 target price on shares of Celldex Therapeutics in a research note on Wednesday. BidaskClub raised Celldex Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 6th. Finally, WBB Securities reissued a “buy” rating and set a $10.00 target price on shares of Celldex Therapeutics in a research note on Wednesday, December 6th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $6.38.
Celldex Therapeutics (NASDAQ:CLDX) last posted its earnings results on Wednesday, March 7th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.08. Celldex Therapeutics had a negative return on equity of 44.64% and a negative net margin of 730.06%. The business had revenue of $3.50 million during the quarter, compared to analysts’ expectations of $1.49 million. During the same period in the prior year, the business earned ($0.30) EPS. Celldex Therapeutics’s revenue for the quarter was up 87.2% compared to the same quarter last year. equities research analysts predict that Celldex Therapeutics, Inc. will post -0.89 EPS for the current fiscal year.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.